AdvanCell reports 80% PSA response with ADVC001 in updated Phase 1 prostate cancer study
AdvanCell reports an 80% PSA response and 11.2-month median rPFS with ADVC001. Small Phase 1 numbers leave important efficacy questions.
Pharma & Biotech
Pharma & Biotech
Vir Biotechnology’s VIR-5500 tests whether dual-masked T-cell engagers can finally work in metastatic prostate cancer
Vir Biotechnology’s VIR-5500 shows early promise in metastatic prostate cancer. Find out what changes, what remains uncertain, and what comes next.